Table 3 Clinical and biological characteristics of the 70 CLL patients whose samples were used in the functional verification experiments
characteristics | N = 70 | |
|---|---|---|
Male, n (%) | 38(54.3) | |
Median age (range), years | 57(30–87) | |
Binet stage, n (%) | Stage A | 13(18.6) |
| Â | Stage B/C | 57(81.4) |
Presence of B-symptoms, n (%) | Â | 12(17.1) |
MBC > 5 × 109/L, n (%) |  | 58(82.0) |
Platelets < 100 × 109/L, n (%) |  | 23(32.9) |
Hemoglobin < 100 g/L, n (%) |  | 15(21.4) |
CD4/CD8 | < 1, n (%) | 16(22.9) |
|  | > 2.5, n (%) | 9(12.9) |
β2-MG > 3.5 mg/L, n (%) |  | 25(35.7) |
Unmutated IGHV, n (%) | Â | 28(40) |
Del(17p) or TP53 mutation, n (%) | Â | 10(14.3) |
Del(13q), n (%) | Â | 23(32.9) |
Del(11q), n (%) | Â | 6(8.6) |
Risk stratification, n (%) | low | 20(28.6) |
| Â | medium | 20(28.6) |
| Â | high | 20(28.6) |
| Â | very high | 10(14.2) |